Healthcare / BiotechnologyShenzhen
$34.34
-1.27 (-3.57%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-28.5M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
49/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.8B
P/E
107.3x
↑EV/EBITDA
56.9x
↑ROE
3.4%
↑Gross Margin
27.4%
↓Debt/Equity
0.16
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+12.9%
FCF CAGR
—
FCF margin
13.4%
FCF / Net income
2.69x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $688.4M · net income $34.3M · FCF $92.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $688.4M | $688.4M | $544.5M | $489.7M | $478.9M |
| Net Income | $34.3M | $34.3M | $17.1M | $37.6M | $67.2M |
| EBITDA | $88.1M | $88.1M | $61.9M | $77.8M | $106.1M |
| EPS | 0.24 | 0.24 | 0.12 | 0.27 | 0.61 |
| Gross Margin | 27.4% | 27.4% | 23.9% | 30.9% | 36.9% |
| Operating Margin | 6.3% | 6.3% | -0.6% | 8.8% | 14.0% |
| Net Margin | 5.0% | 5.0% | 3.1% | 7.7% | 14.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.16 | 0.16 | 0.18 | 0.18 | 0.09 |
| Current Ratio | 4.08 | 4.08 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $92.2M | $92.2M | $-28.5M | $-227.4M | $-24.7M |
| Returns | |||||
| ROE | 3.4% | 3.4% | 1.7% | 3.4% | 6.0% |
| Valuation | |||||
| P/E | 107.31 | 107.31 | 208.33 | 97.44 | 50.39 |
| EV/EBITDA | 56.91 | 56.91 | 59.08 | 47.17 | 25.65 |
| P/B | 4.89 | 4.89 | 3.45 | 3.28 | 3.04 |
| Growth & Yield | |||||
| Revenue Growth | 26.4% | 26.4% | 11.2% | 2.3% | — |
| EPS Growth | 100.0% | 100.0% | -55.6% | -55.6% | — |
| Dividend Yield | 0.4% | 0.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
133.3%
EPS terminal req.
$3.05
Spread vs growth
-33.3%
5Y implied EPS CAGR
72.7%
EPS terminal req.
$3.69
Spread vs growth
27.3%
10Y implied EPS CAGR
37.8%
EPS terminal req.
$5.94
Spread vs growth
62.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+13.8%
Start / end P/E
252.3x → 143.1x
EPS bridge
0.12 → 0.24
Residual
-43.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.